ERBB2 and breast cancer: In the OlympiA study (NCT02032823), 1 year of adjuvant olaparib treatment after completion of neoadjuvant or adjuvant chemotherapy and local treatment resulted in significantly longer invasive and distant disease-free survival and fewer deaths compared with placebo in patients with gBRCAm, HER2-negative, high-risk early BC [24, 25].